Nitric oxide regulation of cGMP production in osteoclasts

Abstract

Bone resorption by osteoclasts is modified by agents that affect cyclic guanosine monophosphate (cGMP), but their relative physiological roles, and what components of the process are present in osteoclasts or require accessory cells such as osteoblasts, are unclear. We studied cGMP regulation in avian osteoclasts, and in particular the roles of nitric oxide and natriuretic peptides, to clarify the mechanisms involved. C-type natriuretic peptide drives a membrane guanylate cyclase, and increased cGMP production in mixed bone cells. However, C-type natriuretic peptide did not increase cGMP in purified osteoclasts. By contrast, osteoclasts did produce cGMP in response to nitric oxide (NO) generators, sodium nitroprusside or 1-hydroxy-2-oxo-3,3-bis(3-aminoethyl)-1-triazene. These findings indicate that C-type natriuretic peptide and NO modulate cGMP in different types of bone cells. The activity of the osteoclast centers on HCI secretion that dissolves bone mineral, and both NO generators and hydrolysis-resistant cGMP analogues reduced bone degradation, while cGMP antagonists increased activity. NO synthase agonists did not affect activity, arguing against autocrine NO production. Osteoclasts express NO-activated guanylate cyclase and cGMP-dependent protein kinase (G-kinase). G-kinase reduced membrane HCI transport activity in a concentration-dependent manner, and phosphorylated a 60-kD osteoclast membrane protein, which immunoprecipitation showed is not an H+-ATPase subunit. We conclude that cGMP is a negative regulator of osteoclast activity. cGMP is produced in response to NO made by other cells, but not in response to C-type natriuretic peptide. G-kinase modulates osteoclast membrane HCI transport via intermediate protein(s) and may mediate cGMP effects in osteoclasts.

Possible Association between Erectile Dysfunction and Osteoporosis in Men

“…Also, various animal models indicate that elevated levels of NO, as well as elevated levels of NO donors, inhibit bone resorption (Kasten et al, 1994). Nitric oxide has been shown to regulate osteoclasts, which are responsible for bone resorption (Dong et al, 1999). Bone formation and resorption are key processes that are necessary for the constant remodelling that occurs in bone tissue to keep it healthy, and to repair bone micro-damage.…”

ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone

“…Previous studies showed that high levels of cGMP can negatively regulate the ability of osteoclasts to resorb bone, disrupting their attachment to the bone surface and preventing efficient secretion of HCl [76,77]. However, an important phase of the bone resorption mediated by osteoclasts is their ability to break the sealing zone, detach from the bone surface, migrate to a new area of bone, and reinitiate bone resorption.…”

Functional osteoclast attachment requires inositol-1,4,5-trisphosphate receptor-associated cGMP-dependent kinase substrate

“…It was observed over a decade ago that PKG modifies cell membrane-associated proteins in osteoclasts, 30 although how cell membrane-associated proteins are selectively targeted was obscure. There are limited precedents for cell membrane protein regulation by IRAG, although IRAG was identified by screening a membrane-related protein complex in tracheal epithelial cells.…”